The FDA has broadened the indication for evolocumab (Repatha; Amgen) to include adults at increased risk of major adverse ...

Jonathan Thompson, MD, MS, explains how financial, insurance, and socioeconomic barriers limit equitable access to biomarker ...

A clinical trial assessing a remote weight loss intervention in women with breast cancer saw a reduction in body weight.

New findings demonstrate an association between increased cumulative depression genetic burden and multiple sclerosis (MS) ...

Clonally expanded CD8+ T cells appear to play a causal role in the initiation and progression of alopecia areata.

Brensocatib, the first FDA-approved dipeptidyl peptidase 1 (DPP1) inhibitor for non–cystic fibrosis bronchiectasis, may have broader potential for other neutrophil-driven conditions, according to ...

Ravi Vij, MD, MBA, explains how insurance-related delays in CAR T approval slow treatment initiation, increase interim therapy costs, and contribute to patient burden.

Treatment challenges that Anasuya Gunturi, MD, PhD, encounters in her work at Lowell General Hospital include language ...

“SWIFT-seq is a powerful option as it can measure the number of CTCs, characterize the genomic alterations of the tumor, ...

Real-world evidence on infection risks from multiple sclerosis treatments remains limited, with inconsistent findings ...

Patients with chronic lymphocytic leukemia (CLL) had significantly lower monocyte-to-lymphocyte ratio values compared with ...

Synthetic generation replicates key clinical patterns from real-world data, enabling valid analyses with fewer patients.